Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals
Eugenia Galeota,Valeria Bevilacqua,Andrea Gobbini,Paola Gruarin,Mauro Bombaci,Elisa Pesce,Andrea Favalli,Andrea Lombardi,Francesca Vincenti,Jessica Ongaro,Tanya Fabbris,Serena Curti,Martina Martinovic,Mirco Toccafondi,Mariangela Lorenzo,Angelica Critelli,Francesca Clemente,Mariacristina Crosti,Maria Lucia Sarnicola,Manuele Martinelli,Lucia La Sala,Alejandro Espadas,Lorena Donnici,Maria Orietta Borghi,Tullia De Feo,Raffaele De Francesco,Daniele Prati,Pier Luigi Meroni,Samuele Notarbartolo,Jens Geginat,Andrea Gori,Alessandra Bandera,Sergio Abrignani,Renata Grifantini
DOI: https://doi.org/10.1016/j.clim.2024.110164
Abstract:Multiple vaccines have been approved to control COVID-19 pandemic, with Pfizer/BioNTech (BNT162b2) being widely used. We conducted a longitudinal analysis of the immune response elicited after three doses of the BNT162b2 vaccine in individuals who have previously experienced SARS-CoV-2 infection and in unexperienced ones. We conducted immunological analyses and single-cell transcriptomics of circulating T and B lymphocytes, combined to CITE-seq or LIBRA-seq, and VDJ-seq. We found that antibody levels against SARS-CoV-2 Spike, NTD and RBD from wild-type, delta and omicron VoCs show comparable dynamics in both vaccination groups, with a peak after the second dose, a decline after six months and a restoration after the booster dose. The antibody neutralization activity was maintained, with lower titers against the omicron variant. Spike-specific memory B cell response was sustained over the vaccination schedule. Clonal analysis revealed that Spike-specific B cells were polyclonal, with a partial clone conservation from natural infection to vaccination. Spike-specific T cell responses were oriented towards effector and effector memory phenotypes, with similar trends in unexperienced and experienced individuals. The CD8 T cell compartment showed a higher clonal expansion and persistence than CD4 T cells. The first two vaccinations doses tended to induce new clones rather than promoting expansion of pre-existing clones. However, we identified a fraction of Spike-specific CD8 T cell clones persisting from natural infection that were boosted by vaccination and clones specifically induced by vaccination. Collectively, our observations revealed a moderate effect of the second dose in enhancing the immune responses elicited after the first vaccination. Differently, we found that a third dose was necessary to restore comparable levels of neutralizing antibodies and Spike-specific T and B cell responses in individuals who experienced a natural SARS-CoV-2 infection.